Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Harrow, Inc. commercializes ophthalmic disease management products in North America, with a portfolio used in dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, ocular surface conditions and retina diseases. Its recurring news includes financial results and stockholder letters, commercial product updates for therapies such as VEVYE, ILEVRO, IOPIDINE and TRIESENCE, and distribution arrangements supporting U.S. product availability.
Company updates also cover reimbursement and regulatory developments, scientific presentations in ophthalmology, clinical development for label expansion, product launches and capital actions such as senior unsecured notes. Harrow reports through branded ophthalmic pharmaceuticals and ImprimisRx, reflecting both commercial products and specialty ophthalmic medication operations.
Melt Pharmaceuticals announces the appointment of Brad Osborne as Chief Financial Officer, bringing over 20 years of finance experience, including a decade at Precigen. His expertise spans IPOs, M&A, and SEC compliance. Dr. Larry Dillaha, CEO, emphasizes Osborne's significant role in guiding the company through its ongoing Phase 2 efficacy study for MELT-300 and advancing their patented MELT technology. Melt focuses on non-intravenous and non-opioid sedation solutions, carved out from Harrow Health in 2019, catering to over 100 million medical procedures in the U.S.
Harrow Health (NASDAQ: HROW), an ophthalmic healthcare company, will report its financial results for Q4 and the full year 2021 on March 10, 2022, after market close. A conference call is scheduled for 4:45 p.m. ET the same day to discuss results and provide business updates. Investors can access the Letter to Stockholders on the company's website following the earnings release. Harrow Health focuses on ophthalmic pharmaceuticals through its subsidiaries, ImprimisRx and Visionology.
Harrow Health, Inc. (Nasdaq: HROW) announced that the FDA has accepted its New Drug Application (NDA) for AMP-100, aimed at ocular surface anesthesia. The application has a PDUFA date of October 16, 2022.
CEO Mark L. Baum emphasized that if approved, AMP-100 would be the first non-opioid ophthalmic drug of its kind in the U.S. Harrow Health is committed to making this innovative drug commercially available to ophthalmologists and surgery centers nationwide.
Harrow Health, Inc. (NASDAQ: HROW), a healthcare company focused on ophthalmology, announced that CEO Mark L. Baum and CFO Andrew Boll will present at the Aegis Capital Corp. Virtual Conference from February 23-25, 2022. Their presentation is scheduled for February 24, 2022, at 3:30 p.m. ET. To view the presentation, attendees can access the link on Harrow Health's website in the events section. Harrow Health operates ImprimisRx and Visionology, and holds equity positions in Eton Pharmaceuticals, Surface Ophthalmics, and Melt Pharmaceuticals.
Harrow Health, Inc. (NASDAQ: HROW) has released its inaugural 2022 Corporate Transparency Report, emphasizing its commitment to making sight-saving medications accessible. CEO Mark L. Baum highlights sustainable business practices aimed at benefiting customers and communities. The report details the company’s dedication to innovation, quality, and ethical standards while maintaining strong corporate governance. Harrow Health operates ImprimisRx and Visionology, and holds equity positions in affiliated companies. The report is available in the Investors section of the company’s website.
NASHVILLE, Tenn. -- Harrow Health (NASDAQ: HROW) announced participation in the virtual H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO Mark L. Baum and CFO Andrew Boll will represent the company. A pre-recorded presentation will be available on Harrow's investor relations website starting January 10 at 7:00 a.m. ET, remaining accessible for 90 days. Harrow Health specializes in ophthalmic healthcare and operates ImprimisRx and Visionology, focusing on innovative eye care solutions.
Melt Pharmaceuticals announced the filing of two INDs with the FDA for non-opioid formulations MELT-210 and MELT-400. The company is actively dosing patients for its Phase 2 pivotal efficacy study of MELT-300, which is expected to complete enrollment by early Q2 2022. MELT-300 offers a needle-free, opioid-free alternative for sedation during cataract surgeries, potentially eliminating the need for opioids and contributing to addressing the opioid crisis. Top-line results are anticipated by the end of Q2 2022.
Harrow Health (NASDAQ: HROW) announced the acquisition of U.S. commercialization rights for four FDA-approved ophthalmic medications from Novartis for $14 million. The products include IOPIDINE®, MAXITROL®, and MOXEZA®, which will enhance Harrow's portfolio in the ophthalmic surgical and acute care markets. This acquisition positions Harrow as a unique provider of both branded products and compounded formulations in the U.S. market, leveraging its ImprimisRx platform for distribution.
Harrow Health, Inc. (Nasdaq: HROW) has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective December 20, 2021. This inclusion is a recognition of the company's performance among biotechnology and pharmaceutical securities. CEO Mark L. Baum expressed pride in this milestone, viewing it as validation of the team's efforts to create value for stakeholders. Harrow Health focuses on ophthalmic healthcare, operating ImprimisRx and Visionology, and has interests in other pharmaceuticals. The company aims to provide innovative and affordable eye care solutions.
Harrow Health reports record revenues of $18.7 million for Q3 2021, marking a 30% increase from $14.4 million in the same period last year. The company maintains a gross margin of 74% and achieved commissions from DEXYCU® sales of $900,000. Harrow acquired two FDA drug candidates, AMP-100 and MAQ-100, aiming to enhance its product offerings. Cash and cash equivalents stood at $57.9 million as of September 30, 2021. CEO Mark L. Baum emphasized strong revenue growth, despite challenges posed by COVID-19.